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Abstract
Genome-wide distribution of AcAPE1 and its implications in DNA repair and transcription
Mason Tarpley, M.S.
University of Nebraska Medical Center, 2022
Advisor: Kishor K. Bhakat, Ph.D.
Endogenous DNA damage can occur throughout the genome and is resolved through the Base
Excision Repair (BER) pathway. The apurinic/apyrimidinic sites that result from endogenous
DNA damage, called AP-sites, are created by DNA glycosylases removing oxidized or modified
bases. These AP-sites are primarily repaired by AP endonuclease 1 (APE1) through the BER
pathway. Modification of APE1 by acetylation of specific lysine residues in the proteins’
unstructured, N-terminal tail, have been shown to increase the residence time of APE1 (AcAPE1)
at the AP-sites. It is unknown where AcAPE1 is binding to chromatin in the genome. Here, we
are testing the hypothesis that DNA damage influences the genomic locations of AcAPE1
binding.
By using ChIP-seq with a specific antibody for AcAPE1 we can accurately map the
chromatin regions that are bound by AcAPE1. Our AcAPE1 ChIP-seq data shows a high
localization of AcAPE1 in promoter regions of genes. Correlating our AcAPE1 ChIP-seq data
with publicly available histone markers and ATAC-seq data confirmed our finding that AcAPE1
has preferential binding for open chromatin regions that are near genes. When introducing
oxidative DNA damage by hydrogen peroxide treatment (H2O2), we see no noticeable changes in
AcAPE1 binding. These results have been replicated in multiple cell lines.
We have found that AcAPE1 has a strong preferential for binding to the promoter regions
of genes. While we can accurately map AcAPE1 to gene-rich regions, we have yet to determine
the reason for this preferential binding. It was expected that with oxidative DNA damage the
i
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distribution of AcAPE1 would change but this does not seem to be the case. In the future we
would like to use ChIP-seq data for other proteins known to play a role in the BER pathway to
help determine if the role of the AcAPE1 is related to DNA damage or some other function.
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Chapter 1

Introduction
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Overview of Base Excision Repair.
The genome is under continuous attack from DNA damaging agents. DNA damage can occur
from many different sources, both endogenous, such as products resulting from cellular
metabolism, and exogenous, such as alkylating agents, radiation, and exposure to chemicals[1-3].
These endogenous and exogenous sources of damage may result in oxidation, alkylation, or
deamination-mediated base damages, which may lead to single-strand breaks (SSBs) and
Apurinic/Apyrimidinic (AP) sites[4]. Base Excision Repair (BER) is the main DNA damage
response pathway that is responsible for alleviating these types of damaged DNA[5-7]. AP sites
are reported to be the most common type of endogenous DNA damage, found throughout the
genome. They have many known harmful effects on DNA processes, including interfering with
DNA replication and transcription, and mutagenesis that may result in deletions, insertions, or
substitutions[8, 9]. Therefore, repair of AP sites is essential for maintaining cellular functions and
genome integrity.
The human Apurinic/Apyrimidinic (AP) Endonuclease (APE1) is the primary enzyme
responsible for repairing AP sites throughout the genome via the highly conserved BER pathway.
Studies in the 1970s first discovered thousands of AP sites accumulate in the genome in each
cell[10]. Later studies further identified and characterized the enzymes involved in repairing the
AP sites and were able to begin elucidating the multiple coordinated steps of the BER pathway[2,
11]. The BER pathway initiates with the removal of the damaged base, leaving an AP site that
APE1 protein is able to recognize[12]. The conversion of damaged bases to AP sites necessary
for APE1 recognition is mediated by two distinct classes of DNA glycosylases. The two classes
of lesion-specific DNA glycosylases are monofunctional glycosylases, which only possess DNA
glycosylase activity, and bifunctional glycosylases, which possess both DNA glycosylase and
DNA strand cleavage activity[13]. Initial steps in the BER pathway differ depending on the
glycosylase class acting on the damaged base. Monofunctional glycosylases cleave the damaged
2
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base, resulting in the formation of an AP site. APE1 then cleaves the AP site, revealing a single
base gap that is flanked by 5’-dRP (deoxyribose phosphate) and 3’-OH. The 5’-dRP is an abasic
sugar phosphate residue found at the site of single-strand breaks. This single base nick is
recognized by polymerase β (Pol β) and repaired. In contrast, bi-functional glycosylases have
dual functions of damaged base removal and cutting of the DNA backbone to create a single base
gap. Bi-functional glycosylases catalyze β-elimination, where the single base gap is flanked by
5’-phosphate and 3’-α,β-unsaturated aldehyde, or by β,δ-elimination, leaving a 5’-phosphate and
a 3’-phosphate residue. Two prominent bi-functional glycosylases are the 8-oxoguanine (8-oxoG)
DNA glycosylase (OGG1) and Nth Like DNA Glycosylase 1 (NTH1). Following action by
OGG1 and NTH1, the 3’-α,β-unsaturated aldehyde is removed by APE1, leaving behind a 3’hydroxyl group that can be recognized by Pol β, similar to the process that occurs when the
damaged base is recognized by a monofunctional DNA glycosylase[14]. In this way, APE1 plays
an essential role in the BER pathway[15]. Pol β is then able to insert the complimentary base into
the nick, and downstream proteins Lig III and XRCC1 are able to seal the DNA backbone[16-18].
This single-base repair mechanism is commonly known as short-patch BER[19] (Figure 1).
When the 5’-dRP is unable to be recognized by Pol β, there is a separate process that needs to
occur to fix the nick in the DNA backbone. AP sites that are modified, either oxidized or reduced,
are unable to be processed by β-elimination[20]. In this case, there is a short (2-8 base pair)
section that gets added to the 5’-dRP, creating a flap[20]. This flap is recognized by FEN1, which
excises this section in a PCNA-dependent fashion. In the presence of PCNA, Lig I repairs the
remaining gap in the DNA backbone. This process is commonly referred to as long-patch BER
pathway[21]. Previous studies have determined that long-patch BER, while infrequent, is
prevalent in cells that are depleted of ATP, which can result in insufficient adenylation of DNA
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Figure 1: Schematic diagram of the BER pathway. Base Excision Repair (BER) pathway is
turned on by the damage of a single base and subsequent removal by a damage specific DNA
glycosylase, creating an AP site. Subsequently, APE1 excises the AP site, DNA polymerase fills
in the resulting DNA SSB, and DNA ligase III seals the broken strand.
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ligases[22]. Poly(ADP-ribose) polymerase-1 (PARP-1) generates the ATP that is necessary to
adenylate the ligase, which in turn fully repairs the DNA[22]. While there two distinct directions
BER can take, both fully repair the DNA lesion in a highly regulated and coordinated process that
involves many enzymes and proteins that interact, and are recruited to, the site of DNA
damage[23]. While APE1 is best known for the important role it plays in BER, it plays other roles
in the cell. APE1 is a highly multifunctional protein that plays many different roles in
transcriptional regulation, which will be explored further by this study.
Overview of APE1.
APE1 is shown to be an essential protein. Groups have tried to create APE1-null mice but they
are early embryonic lethal, resulting in no APE1-null mouse embryonic fibroblast (MEF) cell
lines being created[24]. While it is unclear exactly which role of APE1 is essential in early
embryogenesis, APE1 is known to play a major role in BER pathway, which would be important
in maintaining DNA stability during early embryogenesis. Studies have also shown that APE1 is
necessary for embryonic hematopoiesis and CD40-mediated B-cell activation[25-27]. This would
point to the redox function of APE1 as being essential in regulating immune responses through
activation of specific B-cell transcription factors Pax5 and EBF[25]. Studies on multiple cancer
cell lines and MEF cells have shown that APE1 inactivation leads to apoptosis, making it an
interesting protein to study as a cancer therapeutic[28, 29].
Human APE1 (also known as APEX1) can be found on chr14q11.2, and encodes a protein
with 318 amino acids, with a theoretical weight of 35.5 kDa[7]. APE1 can be found in the nucleus
of all tissues, leading researchers to believe it has an essential function in all cells. There is an
evolutionary highly conserved, rigid, globular C-terminal nuclease domain[30, 31]. Mammalian
APE1 has an evolutionarily novel disorganized N-terminal tail that is not found on yeast ortholog
Apn1. The N-terminal tail is 60 nucleotides long, is highly positively charged, and contains
nuclear localization signals (NLSs)[32]. Unlike its E. coli counterpart Xth1, APE1 is a
5
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multifunctional protein and is involved in multiple processes within the cell. While APE1 is best
known for its role in recognizing and excising AP sites in the BER pathway, it can also act as a
transcriptional regulator through redox activation of multiple transcription factors, such as p53,
NF-κB, HIF1α, and Egr1[33, 34]. The N-terminal 1-127 amino acids, including the disordered
domain, are responsible for the redox function of APE1 in humans[7]. It may also aid in APE1
interactions with other proteins, whereas the C-terminal domain mainly functions in DNA
binding and DNA backbone cleavage[35]. The independent N-terminal and C-terminal functional
domains allow for APE1 to have a wide array of roles inside the cell.
APE1 Nuclease Function.
APE1 is a nuclease that can cleave the 5’ end of the AP sites, and is capable of acting as either an
endonuclease, 3’ phosphodiesterase, 3’ to 5’ exonuclease, or RNA cleavage enzyme[15]. The
most well characterized nuclease function of APE1 is its ability to cleave the phosphodiester
backbone of DNA at the AP site at the 5’ end, creating a nick in the DNA with a 3’-hydroxyl and
5’-dRP termini[36]. Important residues in this function include N68, D70, Y171, N212, D283,
and D308, with D210 and H309 showing to be critical in the hydrolytic reaction, and E96 playing
a critical role in divalent metal coordination[30, 35]. Experiments in whole cell extracts have
shown that APE1 is the rate limiting protein of the BER pathway, meaning that the rapid catalysis
of AP sites by APE1 is followed by slow release of products[37]. This slow catalysis of
downstream intermediates of BER pathway may be a way to limit the number of cytotoxic
intermediates released by BER, including reactive oxygen species (ROS). Another reason for this
slow catalysis could be to aid in the coordination of further BER pathway steps. The slow
catalysis would allow time for necessary downstream proteins to be recruited to the site of
endogenous DNA damage. Also, it was shown in colon, breast, and ovarian cancer that blocking
APE1 DNA repair activity by methoxyamine (MX) resulted in increased tumor cell sensitivity
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when treated in combination with alkylating agents such as BCNU and temozolomide (TMZ)[3842].
APE1 Redox Function.
APE1 also has a redox function that regulates the binding of transcription factors to DNA[34]
(Figure 2). The redox function and DNA binding functions of APE1 are carried out by
independent functional domains, and mutations to one domain do not affect the functionality of
the other in vitro[7, 43]. APE1 redox function has been shown to stimulate DNA binding of many
stress-inducible transcription factors such as P53, HIF1α, NF-κB, Pax8 and more, via reducing
cysteine residues in their DNA binding domain[44-47]. This redox function is only found in
mammalian APE1, meaning APE1 is still evolving, and was thought to be dependent on the
function of three Cysteine (Cys) amino acids found in the N-terminal tail; C65, C93, and
C99[48]. Of these, only C65 is required for redox function as shown by mutating a Threonine
(Thr) to Cys in zebrafish at the same location as human APE1 C65, resulting in the gain of redox
function[48]. Site directed mutagenesis studies also pointed to C65 as being the important redox
active site[49]. These results were further corroborated by NMR studies that thioredoxin (TRX),
which can reduce oxidized proteins, interacts with C65 containing oligos[50, 51]. Neurons
submitted to oxidative stress showed high levels of apoptosis, but the rate of apoptosis was
slowed when treated with ectopic WT APE1, and to a lesser extent, Cys65Ala mutant, also
pointing to C65 as being the amino acid required for APE1 redox activity[52].
It was proposed that APE1 may exist in two conformations, a native, tightly folded state,
and a partially unfolded state[53]. These two conformational states are involved in further
regulating the redox function of APE1. The partially unfolded state would allow transcription
factors and the C65 residue to create a thiol-mediated/disulfide exchange. Small molecule
inhibitor APX3330 is able to suppress the redox function of APE1 by binding to the C65 and C93
sites of the partially unfolded APE1 by forming disulfide bonds between APX3330 and the amino
7
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Figure 2: APE1 Redox Activity. Representative diagram of APE1 acting as a redox factor to
activate downstream transcription factors, such as NF-κB, by reduction of the intramolecular
disulfide bond to its reduced SH form by oxidation of C65 and C93, allowing activation of target
gene transcription.
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acids[54]. Inactivation of the redox function of APE1 reduces activation of some target
transcription factors of APE1[55]. APX3330 has shown some promise as a targeted APE1
inhibitor in cancer cells, and is being evaluated in clinical trials[44].
APE1 Transcription Regulatory Function.
Human APE1 was cloned in the early 1990s by Demple, Hickson, and Seki labs[56]. At about the
same time, Curran’s group discovered APE1 as a new protein that was the major binding factor
that controlled the binding of AP-1 transcription factor complex to chromatin, which they called
REF-1[57, 58]. Similar regulation of other transcription factor complex binding, including NFκB, through the reduction of cysteine residue in the DNA binding domain was observed. Shortly
after, Okazaki’s group discovered that APE1 could directly bind negative Ca2+ response elements
(nCaRE) sequences, modulating gene expression via acting as a direct trans-acting factor[59]. His
group found that PTH has two nCaRE sequences in its promoter (nCaRE-A and nCaRE-B) that
APE1 can bind and influence the expression of PTH. Stable binding of APE1 to nCaRE
sequences is Ca2+-dependent and modulated through its N-terminal tail, though the N-terminal tail
may not be sufficient for binding. In the presence of increased Ca2+, APE1 is found to have higher
levels of acetylation (AcAPE1) due to p300 HAT increased activity, which acts in a calcium
dependent manor. The increase in p300 HAT activity may be due to catalysis, caused by protein
kinase C or Ca2+ calmodulin (CAM) IV, inducing phosphorylation of p300. Through these
nCaRE-B sequences, APE1 can regulate many more genes than originally found in only nCaRE
sequences. It is speculated that the nCaRE-B sequences ability to form a cruciform-like structure
is important in recruiting APE1 to the sequence. Others have shown that while APE1 binding to
nCaRE sequences is Ca2+-dependent, overexpression of APE1 can result in APE1 binding to
nCaRE sequences in a Ca2+-independent manner. Later, it was also found that APE1 is present in
nCaRE-B complexes in human and mouse renin gene promoters[60].
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This role of APE1 as a component of transcriptional complexes in promoter regions
extends to additional genes including vascular endothelial growth factor (VEGF), PTEN, and
multidrug resistance MDR1. APE1 stably interacts with HIF-1α and STAT3, CBP/p300, and
APE1 are components of a transcriptional complex that regulates Src-dependent hypoxia-induced
expression of VEGF in pancreatic and prostate carcinomas[61]. Similarly, APE1 interacts with
Egr-1 and stimulates PTEN expression. It was found that for Egr-1 to stimulate PTEN expression,
APE1 must be acetylated[62]. This was confirmed using HDAC inhibitors in HeLa cells,
resulting in increased acetylation of APE1 and induced PTEN expression[62]. HeLa cells that had
downregulated APE1 did not show the same induction of PTEN expression, further confirming
the role of AcAPE1 in PTEN expression[62]. APE1 was found to interact with YB-1 on MDR1
promoter to activate its expression[63]. Interactions of APE1 with estrogen receptor (ER) alpha
was shown to be important for many ER-dependent gene expressions. Redox-inactive Cys65Ser
and Cys138Ser APE1 mutants modulate YB-1-mediated MDR1 promoter activity in a similar
manor to WT APE1[63]. This result leads us to believe APE1s redox activity is not required in
MDR1 activation. Together, these studies indicate redox-independent transcriptional function of
APE1 regulates HIF-1α, Egr-1, and YB-1 gene expression giving rise to a potential third role of
APE1: trans-acting factor.
The interactions APE1 is required to make in these trans-acting complexes may be
accomplished through the unstructured N-terminal tail. Studies investigating the N-terminal tail
found that deleting aa1-116 resulted in abolishing NF-κB activation by APE1, leading to cell
death when treated with tumor necrosis factor (TNF)[32]. Other studies have previously shown
that post-translational neutralization of positive Lysine residues nullifies protein-protein
interactions and affects gene expression[64, 65]. The exact mechanism by which APE1 acts as a
trans-acting factor in regulating gene expression has not been fully elucidated.
Post-Translational Modifications of APE1.
10
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Post-translational modifications (PTMs) such as acetylation, ubiquitination, phosphorylation, and
methylation of proteins allow multiple functions to be more precisely controlled and specific,
including cellular localization, turnover rates, binding functionality, and protein efficacy.
Unstructured regions are common hotspots for post-translational modifications, due to their
accessibility to residues[66]. It has been shown that many proteins involved in BER can be
acetylated, but the function of acetylation in this context is not yet clear.[67-71]. The interactions
between these modifications and nearby proteins are still an area yet to be explored, including
those of APE1.
Many posttranslational modifications of APE1 have been studied, including
phosphorylation, acetylation, ubiquitination, nitrosylation, and glutathionylation, with their
respective activity shown to affect either nuclease function or redox function, but not both. Our
lab previously discovered acetylation of multiple Lysine residues (K6, 7, 27, 31 and 32) in the Nterminal domain by histone acetyltransferase p300, both in vivo and in vitro[64, 72]. Acetylation
of K27, 31, and 32 is dependent on prior acetylation of residues K6 and K7[69]. K6 and K7 can
both be acetylated, but they cannot be acetylated at the same time due to physical constraints. We
have also created an antibody specific for AcAPE1 that does not recognize unmodified APE1 or
non-acetylable APE1 K6,7R[63]. Using this antibody, we were able to study the acetylated form
of APE1 by immunofluorescence and chromatin immunoprecipitation (ChIP). When acetylated,
APE1 has also been shown to specifically localize to the nucleus, while unmodified APE1 can be
found throughout the cell, including the nucleus. Other groups have shown that deacetylases, such
as SIRT1 and HDAC1, can remove acetylation from APE1 lysine residues[73, 74].
Acetylated APE1 levels have been shown to be elevated in a variety of cancers,
highlighting the importance of studying the various roles of this protein[65, 74]. We have
previously shown that acetylation of APE1 moderately increases the endonuclease function of
APE1 and regulates gene expression through modulation of transcription factor loading on the
11
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chromatin[75]. Through the use of APE1 null MEF cells, our lab has shown that the DNA repair
domain and lysine’s 6 and 7 are crucial to cell survival and proliferation[29]. Due to AP-sites
being detrimental to DNA transcription, it is unsurprising that the DNA repair domain of APE1 is
essential to the survival of cells, but the requirement for acetylable lysine 6 and 7 was less
expected. This acetylation of the N-terminal lysine residues may be necessary for protein-protein
interactions and other DNA repair functions.
The requirement for APE1 to maintain cell proliferation and promote survival may be
due to its role in regulating the expression of hundreds of genes. The N-terminal domain of APE1
and its ability to be acetylated may regulate its AP-endonuclease activity. Although APE1 was
found to be present in a variety of transacting complexes to regulate gene expression, it is largely
unknown how APE1 is recruited to the gene regulatory regions, partly because it does not have
any known DNA sequence-specific binding preference. Recently, our lab showed that APE1 can
be found at guanine (G) rich stretches in regulatory regions of chromatin when AP-sites are
present[75]. Furthermore, this study demonstrated a genome-wide correlation between AcAPE1
occupancy and the formation of secondary DNA structures, called G-quadruplexes (G4).
Background of G-quadruplexes.
While DNA is mostly thought of as having a double helical structure with complementary bases
between the two strands, there are areas where the DNA strands can fold onto themselves, called
non-canonical (non-B) DNA structures. These secondary DNA structures may be the locations of
increased DNA damage because of the stress they place on the chromatin by affecting metabolic
processes and replication-dependent processes[76]. One of these such structures is the Gquadruplex (G4), which can be formed when there are four or more patches of at least three
guanines (G3+N1−nG3+N1−nG3+N1−nG3+) in close proximity to one another[77]. The
guanines of these patches bind to each other through Hoogsteen base-pairing and are stabilized by
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Figure 3: G4 Structure Variations. Schematic diagram showing the differences between the
three known G4 structures. The genes where each structure can be found above the diagram, with
the corresponding genomic sequence below. (Putative Quadruplex Sequence= PQS)
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potassium (K+) or sodium (Na+) ions[77]. There are three known types of G4 structures: parallel,
anti-parallel, and mixed (Figure 3). These G4 structures have been found in large numbers in the
telomeres and near the TSSs of genes. The recent mapping of G4 sites through G4-ChIP-seq
revealed that these G4 formations may play a role in regulating transcription of genes through
their preferential formation in gene promoters, 5’ and 3’ untranslated regions (UTRs), and
telomeres[78-80]. These studies also showed that deregulation of G4 structures leads to telomere
defects, transcriptional dysregulation, replication stress, and genomic instability that may lead to
cancer or other disorders[81-84]. Our lab has previously shown that APE1 can bind to these G4
structures and stabilize them, which may increase the amount of transcription of nearby
genes[85]. Consistent with this, studies from Cynthia Burrow’s group also demonstrated the role
APE1 plays in G4-mediated gene expression[86].
Objectives of the dissertation.
APE1 is a known multifunctional protein that is essential for survival of mammalian cells. The
role of APE1 in Base Excision Repair (BER) DNA damage response pathway has been well
studied. There are also known functions as a redox factor for transcription factors to regulate gene
expression. While many studies have investigated the different roles of APE1, the specific role of
APE1 when bound to the chromatin has not been investigated. Furthermore, acetylation of APE1
leads to chromatin interactions that could result in AcAPE1 being of much greater importance to
the cell than previously anticipated. Using Chromatin Immunoprecipitation (ChIP) sequencing
with an antibody specific for AcAPE1, we can better understand the distribution and preferential
binding of AcAPE1.
Our lab has previously mapped AcAPE1 and determined that AcAPE1 preferentially
binds to transcribed gene regions, especially promoters and the first intron. This rudimentary
mapping was backed up by many targeted approaches, including promoter directed ChIP
qPCR[85]. Furthermore, fluorescence anisotropy (FAN) assay results also reveal that APE1 binds
14
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to G4 oligo. Co-immunoprecipitation (CoIP) and proximity ligation assay (PLA) show that APE1
and G4 are in close proximity to one another and interacting. However, there are several
unanswered questions that need to be addressed. First, whether region-specific enrichment of
AcAPE1 occurs in a cell-specific manner or is a general cellular phenomenon. Second, since
APE1 is not a sequence-specific transcription factor, how is AcAPE1 recruited to the promoter or
enhancer regions. Third, what is the biological significance of the association between AcAPE1
and promoter or enhancer regions. AcAPE1 enrichment at promoters and enhancers of genes
could be due to recruitment of APE1 by AP sites formed in situ, or by the G4 structures which
provide a docking site for APE1. The open chromatin regions of the enhancers and promoters
could be more susceptible to endogenous damage. Based on these previous results, and others,
our central hypothesis is that “acetylated APE1 bound to gene regulatory regions promotes
transcriptional activation of genes by alleviating DNA base damage in these regions”. Our
objectives are to investigate the tendency of AcAPE1 to bind gene regulatory regions through the
use of AcAPE1 ChIP-seq. Furthermore, we will elucidate the role DNA damage plays in
chromatin bound AcAPE1 distribution. We will test the hypothesis by pursuing two aims:
Aim 1. Determine if AcAPE1 preferentially associates with promoters and enhancers of
transcriptionally active genes. To determine AcAPE1 enrichment in promoter and enhancer
regions is not a cell-type-specific phenomenon, and rather a general phenomenon, we will map
the genome-wide occupancy of AcAPE1 by ChIP-seq in different cell lines, including lung
adenocarcinoma A549, breast cancer MDA-MB-231, and pancreatic cancer MIA PaCa-2. Histone
modifications and transcription factors are known markers that delineate chromatin activity and
can easily be correlated with AcAPE1 binding. We will also determine if AcAPE1 has preference
for actively transcribing genes through the use of publicly available GRO-seq data. These
correlations will allow us to gain a larger picture of the role AcAPE1 is playing when bound to
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the chromatin and establish the potential role of AcAPE1 in coordinating repair and gene
expression.
Aim 2. Determine if DNA damage retargets APE1 to new genomic loci. To determine if DNA
damage causes a change in AcAPE1 binding to chromatin we will conduct ChIP-seq in A549
cells under normal conditions, and those that have been treated with hydrogen peroxide (H2O2) to
induce AP sites and map AcAPE1 by ChIP-seq. By using multiple DNA damaging agents we
hope to gain a complete understanding of how AP site effects AcAPE1 localization. We will then
compare the effect of these DNA damaging agents to determine if each has a distinct impact on
AcAPE1 chromatin localization.
ChIP-seq allows us to map the binding locations of AcAPE1 to relatively small regions
throughout the chromatin. By crosslinking AcAPE1 to the chromatin, fragmenting the isolated
DNA, and then immunoprecipitating the DNA that has AcAPE1 bound to it, we will identify loci
preferentially occupied by AcAPE1. We will then correlate with other next-generation
sequencing (NGS) methods, such as Global Run-On sequencing (GRO-seq), and Assay for
Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq). These
correlations will allow us to establish the potential roles of AcAPE1 in coordinating repair and
transcription.
Correlating our AcAPE1 ChIP-seq results with publicly available data for many known
chromatin marks, such as histones, transcription factors (TFs), open chromatin regions (ATACseq), and transcription status (GRO-seq) allows us to elucidate the potential roles of AcAPE1
when bound to chromatin. This study looks to build upon previous studies of APE1 by using
genomic and bioinformatic approaches to answer questions that have not been explored in the
field before. The use of bioinformatic analyses of datasets from multiple previous studies allows
us to quickly correlate many proteins and structures at once to get a larger picture of what may be
occurring in the chromatin of cells. This project will open future studies to test whether the
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association of APE1 occurs through binding to DNA secondary structures, such as G4, in gene
regulatory regions, and whether this novel interaction is a mechanism by which cells
preferentially repair endogenous DNA damage in these regions to maintain transcription.

17

18
Chapter 2
Methods
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Cell Lines and Treatments:
We have used a variety of cancerous and non-cancerous cell lines to provide robust results that
are reproduceable. Lung adenocarcinoma A549 cells (ATCC# CCL-185) were cultured in
DMEM-low glucose medium (Thermo Fisher Scientific) with FBS and antibiotics. Human Colon
cancer HCT116 (ATCC #CCL-247) was grown in MaCoy 5A medium (Thermo Fisher
Scientific). Generation of HCT116 cells stably expressing APE1-shRNA or control shRNA were
described previously[87]. Mouse embryonic fibroblast (MEF) cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) with high glucose (Thermo Fisher Scientific). All cell lines
were authenticated by STR DNA profiling on August 2015 by Genetica DNA laboratories,
Burlington, NC.
Chromatin Immunoprecipitation:
Our ChIP protocol is modified from Bowman et al[88]. For ChIP, enough cells were plated the
day before starting the procedure to ensure 20x106 cells are present. For cells treated with
hydrogen peroxide (H2O2), treatment was performed before removal of media and replacing with
phosphate-buffered saline (PBS). Cells were treated with 0.5 mM H2O2 for 30 minutes in 37⁰ C
incubator. Cells were scraped and suspended in PBS and counted. The next morning media was
removed, and PBS was added. We added formaldehyde to achieve 1% concentration directly to
the suspended cells and rocked for 10 minutes at room temperature. Following cross-linking
reaction, 0.125 M final concentration of glycine was added to quench the reaction and rocked for
5 minutes at room temperature. Cells were then pelleted, and supernatant removed. Resulting
pellet was washed two times with cold PBS, spinning down between washes. The pellet was
resuspended in 1 mL cell lysis buffer (5 mM PIPES pH 8, 85 mM KCl, 0.5% Nonidet P40, water
to final volume) plus protease inhibitors and incubated for 15 minutes on ice. Nuclei were
collected by spinning the cells at 4000 rpm for 8 minutes at 4⁰ Celsius (C). The isolated nuclei
were resuspended in 200 µL ice-cold nuclei lysis buffer (50 mM Tris HCl pH 8.1, 10 mM
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EDTA.Na2, 1% sodium dodecyl sulfate (SDS), water to final volume) plus protease inhibitors
and incubated on ice for 20 minutes. We then added 100 µL of cold IP dilution buffer (0.01%
SDS, 1.1% Triton X-100, 1.2 mM EDTA.Na2 pH 8, 16.7 mM Tris HCl pH 8, 167 mM NaCl,
water to final volume) plus protease inhibitors. Using a Bioruptor, we set the sonicator to run for
30 seconds on, 60 seconds off for 28 cycles on low power to achieve fragmented DNA in the
300-500bp range. To pellet the cellular debris, we centrifuged the tubes at max speed for 10
minutes at 4⁰ C. Supernatant was then transferred to new, clean tubes.
To determine sonicated fragment sizes, we removed 15 µL of supernatant to run on a 2%
agarose gel as quality control. DNA from the sonication control was isolated by adding 185 µL of
IP dilution buffer to get a final volume of 200 µL with 0.5 µL 10 mg/mL RNase A. Reverse
cross-linking was completed by heating samples at 95⁰ C for 15 minutes (or 65⁰ C overnight). We
added 4 µL of 10 mg/mL proteinase K to remove proteins and incubated for 2 hours at 50⁰ C. We
extracted once with Phenol:Chloroform:Isoamyl alcohol (25:24:1) by adding equal volume of
P:C:I and vortexed to mix. The sample was then spun for 5 minutes at top speed in a
microcentrifuge and then the top aqueous layer was transferred to a new tube. DNA was
precipitated using 1 µL of 20 mg/mL RNA-grade glycogen, 0.1x 3M sodium acetate (pH 5.2, 0.3
M final concentration) 2.5x ice-cold ethanol, and incubation of the samples at -80⁰ C for 30
minutes to overnight. Samples were spun for 10 minutes at 15000 rpm at 4⁰ C. The supernatant
was removed, and the pellet was washed with cold 70% ethanol to remove salts and then left to
air dry, usually an hour. Once dry, the pellets were dissolved in 30 µL of UltraPure water and 10
µL was run on a 2% agarose gel to confirm sonication fragment size was between 300-500bp.
For the remaining 285 µL, we diluted 5-fold with IP Dilution buffer plus protease
inhibitors (final volume of 1,425 µL). For input controls, we removed 75 µL (5%) of DNA to a
separate tube. For IP, we added 5µg of antibody and incubated the samples overnight at 4⁰ C
while rocking. For AcAPE1 ChIP, we used homegrown antibodies specific for the acetylated N20
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terminal tail of APE1. ChIP for G-quadruplexes used BG4, MABE917 (EMD Millipore). Next
morning, 20 µL of Protein G Dynabeads (Invitrogen, 10004D) were added and samples were
rocked for 2 hours at 4⁰ C. Beads were collected using a magnetic stand and the supernatant was
discarded. Beads were washed 3 times with 1 mL low salt buffer (0.1% SDS, 1% Trition X-100,
2 mM EDTA pH 8, 20 mM Tris HCl pH 8, 150 mM NaCl, water to final volume) and incubated
for 5 minutes on a rocker at room temperature, with magnetic separation and removal of
supernatant between washes. Beads were then washed 2 times with 1 mL high salt buffer (0.1%
SDS, 1% Triton X-100, 2 mM EDTA pH 8, 20 mM Tris HCl pH 8, 500 mM NaCl, water to final
volume) as above, followed by 2 times with LiCl buffer (10 mM Tris HCl pH 8, 1 mM EDTA pH
8, 0.25 M LiCl, 1% NP40, 1% sodium deoxycholate (SDC), water to final volume), and one time
with TE buffer (10 mM Tris HCl pH 8, 1 mM EDTA pH 8, water to final volume). DNA was
eluted from the beads 2 times with 200 µL freshly prepared IP Elution buffer (0.1 M NaHCO3,
1% SDS, water to final volume) as above, pipetting the eluant into fresh tubes. Sodium chloride
(NaCl, 20 µL of 5 M), Ethylenediaminetetraacetic acid (EDTA, 8 µL of 0.5 M), Tris (16 µL of 1
M) were added, and samples were incubated overnight at 65⁰ C to reverse cross-linking. To the
input DNA, we added 369 µL of IP Dilution buffer and they were taken through reverse crosslinking as well. Next morning, 5.3 µL of 15 mg/mL Proteinase K was added to all eluants and
inputs and they were incubated at 50⁰ C for 2 hours. DNA was extracted with
Phenol:Chloroform:Isoamyl alcohol (25:24:1) by adding equal volume of P:C:I and vortexed to
mix. Samples were spun for 5 minutes at top speed in a microcentrifuge and then the top aqueous
layer was transferred to a new tube. DNA precipitation was done with 1 µL of 20 mg/mL RNAgrade glycogen and 0.1x 3 M sodium acetate (pH 5.2, 0.3 M final concentration) and 2.5x icecold ethanol, incubating at -80⁰ C for 30 minutes to overnight. Samples were then spun in a
microcentrifuge for 10 minutes at 15,000 rpm at 4⁰ C. Supernatant was removed and the pellet
was washed with cold 70% ethanol to remove salts and then let air dry, usually an hour. When the
samples were completely dry, the pellets were dissolved in 30µL of Qiagen EB buffer (10 mM
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Tris pH 8.5). DNA concentrations were checked by Quantus Fluorometer before using for either
library prep or qPCR.
ChIP-seq Library Preparation:
To prepare ChIP DNA for sequencing we added 2 volumes of room temperature SPRI beads
(Beckman Coulter, A63880) and rotated samples for 5 minutes at room temperature. Beads were
captured on a magnetic stand and supernatant was removed. Beads were then washed 2 times
with 200 µL of freshly prepared 80% ethanol, aspirating between washes. Samples were air dried
with caps open, ensuring there was no ethanol left in the tubes. DNA was eluted from the beads in
25.5 µL of EB Buffer for 1 minute at room temperature and supernatant was moved to a new
tube.
For end repair reaction, we added 3 µL of 10X NEB End Repair reaction buffer and 1.5
µL NEB End Repair Enzyme mix to the eluant from cleanup and incubated for 30 minutes at
room temperature. We then added 2 volumes of SPRI beads to the mixture and followed the same
steps as above. DNA was then eluted in 19 µL of EB Buffer. For A-tailing, we took the 19 µL
from the End Repair and added 3 µL 10X NEB Buffer 2 (B7002S), 7 µL 1 mM dATP (NEB,
N0440S), and 1 µL NEB Klenow 3’-5’ exo minus (M0212L). Samples were incubated for 30
minutes in a 37⁰ C water bath. Cleanup with 2 volumes of SPRI beads was completed as before
and samples were eluted in 24 µL of EB Buffer. For adapter ligation, we added 3 µL 2X NEB
quick ligase reaction buffer (B2200S), 1 µL of 1 µM universal adapters, and 2 µL NEB T4 ligase
3’-5’ exo minus (M0202L) to the tubes and incubated them for 1 hour at room temperature (can
be longer)[88]. We conducted SPRI bead cleanup as before with 1.5 volumes of beads, eluting in
22 µL EB Buffer. We then set up 50 µL qPCR reactions by adding 25 µL 2X KAPA SYBR
master mix, 1.5 µL 10 µM PrimerU, and 1.5 µL 10 µM primer number with proper index code to
the labeled tubes (Table 1). Each sample had 25 µL pipetted into two separate PCR tubes and
were quickly placed in the machine to ensure the SYBR was not exposed to light. The qPCR
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machine was set to do 30 seconds at 98⁰ C followed by 18 cycles of 10 seconds at 98⁰ C, 20
seconds at 64⁰ C, and 45 seconds at 72⁰ C. To check that the reaction worked, we looked at the
multicomponent plot to see that the fluorescence was over 100,000 in 10-14 cycles. We
conducted SPRI cleanup with 1.2 volumes of beads as before and eluted in 15 µL of EB Buffer.
Samples were then sent for sequencing at the University of Nebraska Medical Center Genomics
Core.
AcAPE1 ChIP-seq Analysis:
Sequencing was completed at UNMC Genomics Core facility using an Illumina NovaSeq6000
sequencer. Adapter sequences were removed and fastq files were received from the sequencing
facility. Reads were mapped to hg19, or mm10, using bwa mem with default settings to create
SAM files[89]. We transformed the SAM files into bam files using Samtools view (-b -q 10)[90,
91]. Duplicate reads were removed from bam files using Picard tools MarkDuplicates
(REMOVE_DUPLICATES= true) and transformed into bigwig files using bedtools genomecov,
normalized by reads per million mapped reads (RPM) (-bg -scale)[92]. Blacklist regions were
also removed from the analysis[93]. ChIP-seq peaks were called using macs2 callpeak with the
following options (--nomodel --broad -g hs -f BED)[94]. ChIPseeker, in R, was used to determine
the genome-wide distribution of peaks, with promoter regions determined to be ±3Kb from the
TSS and all other options left as default settings[95]. Lists of genes were downloaded from UCSC
including all splice variants[96]. All genome browser visualizations were done with Integrative
Genomics Viewer (IGV)[97, 98]. Gene profiles of AcAPE1 were made using deeptools
plotProfile using RPM normalized bigwig signal files. All fastq files and bigwigs have been
uploaded to Gene Expression Omnibus (GEO) with a later release date.
Publicly Available Data Analysis:
A table of downloaded data is available below (Table 2), with accession numbers. All publicly
available ChIP-seq, GRO-seq, and ATAC-seq data was downloaded as fastq files and mapped to
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hg19 as above. ATAC-seq peaks were called using macs2 callpeak with options (--nomodel -g hs
-f BED). Overlaps of AcAPE1 peaks and ATAC-seq peaks were calculated using bedtools
intersect. Heatmaps of AcAPE1 signal at ATAC-seq peaks were made with deeptools
plotHeatmap with peaks sorted by pileup from the macs2 callpeak output.
All histone modification ChIP-seq datasets were treated the same during analyses. All
peaks were called with macs2 callpeak with options (--nomodel --broad -g hs -f BED). Reasons
for using each dataset are provided in Table 2. Peak overlaps and heatmaps were determined as
above. Spearman correlations of histone markers and AcAPE1 were calculated by deeptools
plotCorrelation as heatmaps. An enhancer list for A549 cells was downloaded from
EnhancerAtlas2.0 and used in combination with overlapping histone marks to determine if they
are active or inactive[99]. Active enhancers were determined to have overlapping H3K27ac
peaks, while inactive enhancers lacked an H3K27ac peak. These classified enhancers were then
used to determine overlap with AcAPE1 ChIP-seq peaks. Enhancers were also classified as
proximal (<3Kb from the nearest genebody) or distal (>3Kb from the nearest genebody). The pvalues were determined by Monte Carlo simulations of 1000 permutations, with significance
given at p<0.001. Gene promoter regions were defined as 500bp upstream from the TSS.
Significance of overlaps between peaks and this region were calculated the same as enhancers.
To determine the transcription status of genes, we used publicly available GRO-seq data.
Paused genes were determined to have a higher GRO-seq signal in the TSS+500bp region than in
the genebody. Elongating genes had more GRO-seq signal in the genebody than the gene start.
Inactive genes were determined to have no GRO-seq signal in either the start region or genebody.
Heatmaps of AcAPE1 and PolR2α signal at the paused and elongating genes were made by
sorting genes by their pausing index, from least paused to most paused, with inactive genes given
separately. To determine the significance, we split the pausing index sorted genes into quartiles
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and determined the RPKM normalized signal of AcAPE1 over these genes. Wilcox test, in R, was
used to determine statistical significance (all p<2.2e-16).
RNA-seq Analysis:
RNA-seq data was obtained previously from our lab[85]. The data was analyzed by Novogene,
including mapping and DE calling [85]. For this study, we focused on the 3,485 differentially
expressed genes. To determine overlap with our AcAPE1 ChIP-seq peaks, we used bedtools
intersectBed. We first divided the DEGs into promoter regions (TSS±500bp) and the genebody
(TSS+500bp to TES). Statistical significance was again determined by Monte Carlo with 1000
permutations (p<0.001).
TruSeq Index

TruSeq Index Sequence

Number
TruSeq Index 1

CAAGCAGAAGACGGCATACGAGATCGTGATGTGACTGGAGTTCA
GACGTGTGCTCTTCCGATC*T

TruSeq Index 2

CAAGCAGAAGACGGCATACGAGATACATCGGTGACTGGAGTTCA
GACGTGTGCTCTTCCGATC*T

TruSeq Index 3

CAAGCAGAAGACGGCATACGAGATGCCTAAGTGACTGGAGTTCA
GACGTGTGCTCTTCCGATC*T

TruSeq Index 4

CAAGCAGAAGACGGCATACGAGATTGGTCAGTGACTGGAGTTCA
GACGTGTGCTCTTCCGATC*T

TruSeq Index 5

CAAGCAGAAGACGGCATACGAGATCACTGTGTGACTGGAGTTCA
GACGTGTGCTCTTCCGATC*T

TruSeq Index 6

CAAGCAGAAGACGGCATACGAGATATTGGCGTGACTGGAGTTCA
GACGTGTGCTCTTCCGATC*T
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TruSeq Index 7

CAAGCAGAAGACGGCATACGAGATGATCTGGTGACTGGAGTTCA
GACGTGTGCTCTTCCGATC*T

TruSeq Index 8

CAAGCAGAAGACGGCATACGAGATTCAAGTGTGACTGGAGTTCA
GACGTGTGCTCTTCCGATC*T

TruSeq Index 9

CAAGCAGAAGACGGCATACGAGATCTGATCGTGACTGGAGTTCA
GACGTGTGCTCTTCCGATC*T

TruSeq Index

CAAGCAGAAGACGGCATACGAGATAAGCTAGTGACTGGAGTTCA

10

GACGTGTGCTCTTCCGATC*T

TruSeq Index

CAAGCAGAAGACGGCATACGAGATGTAGCCGTGACTGGAGTTC

11

AGACGTGTGCTCTTCCGATC*T

TruSeq Index

CAAGCAGAAGACGGCATACGAGATTACAAGGTGACTGGAGTTCA

12

GACGTGTGCTCTTCCGATC*T

TruSeq Index

CAAGCAGAAGACGGCATACGAGATTTGACTGTGACTGGAGTTCA

13

GACGTGTGCTCTTCCGATC*T

TruSeq Index

CAAGCAGAAGACGGCATACGAGATGGAACTGTGACTGGAGTTC

14

AGACGTGTGCTCTTCCGATC*T

TruSeq Index

CAAGCAGAAGACGGCATACGAGATTGACATGTGACTGGAGTTCA

15

GACGTGTGCTCTTCCGATC*T

TruSeq Index

CAAGCAGAAGACGGCATACGAGATGGACGGGTGACTGGAGTTC

16

AGACGTGTGCTCTTCCGATC*T

TruSeq Index

CAAGCAGAAGACGGCATACGAGATCTCTACGTGACTGGAGTTCA

17

GACGTGTGCTCTTCCGATC*T
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TruSeq Index

CAAGCAGAAGACGGCATACGAGATGCGGACGTGACTGGAGTTC

18

AGACGTGTGCTCTTCCGATC*T

TruSeq Index

CAAGCAGAAGACGGCATACGAGATTTTCACGTGACTGGAGTTCA

19

GACGTGTGCTCTTCCGATC*T

TruSeq Index

CAAGCAGAAGACGGCATACGAGATGGCCACGTGACTGGAGTTC

20

AGACGTGTGCTCTTCCGATC*T

Table 1: TruSeq Index Sequences used for ChIP-seq library preparation.

A549 Datasets

Marker Usage:

Done By:

Accession Number:

ATAC-seq

Open Chromatin

T.E. Reddy[100]

ENCSR220ASC

H3K4me2

Promoters

T.E. Reddy[100]

ENCSR410BCN

H3K4me3

Transcription Activation

T.E. Reddy[100]

ENCSR203XPU

H3K9me3

Heterochromatin

T.E. Reddy[100]

ENCSR775TAI

H3K27ac

Active Enhancer

T.E. Reddy[100]

ENCSR783SNV

H3K27me3

Heterochromatin

T.E. Reddy[100]

Downloaded:

P300

T.E. Reddy[100]

ENCSR886OEO

CTCF

T.E. Reddy[100]

ENCSR035OXA

Input

T.E. Reddy[100]

ENCSR838ZAU

c-Jun

Michael

ENCSR048CVK

Snyder[100]
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MYC

Michael

ENCSR000DYC

Snyder[100]
SMC3

T.E. Reddy[100]

ENCSR150EFU

RAD21

T.E. Reddy[100]

ENCSR193NSH

USF2

Michael

ENCSR563FBT

Snyder[100]
GRO-seq

Transcription Status

Ivan Marazzi

GSM1278354

Table 2: Table of downloaded, publicly available ChIP-seq datasets used in this paper.
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AcAPE1 is highly correlated with active chromatin regions.
Our recently published genome-wide binding analysis of AcAPE1 in lung cancer A549 and colon
cancer HCT116 cells revealed that AcAPE1 ChIP-seq peaks are enriched in promoters and
enhancers of transcribed gene regions [85]. These experiments were possible due to the creation
of an AcAPE1-specific antibody which was previously shown to be specific for AcAPE1, and not
unmodified APE1 [63]. Furthermore, the specificity of this antibody was confirmed by the
disappearance of AcAPE1 peaks in HCT116 cells expressing APE1-specific shRNA compared to
isogenic wild type (WT) HCT116 cells [63]. Using this antibody for ChIP-seq in A549 cell line
we found 40,582 highly enriched AcAPE1 binding sites genome-wide (Fig 1A). To determine if
promoter/enhancer-specific enrichment of AcAPE1 is conserved across cell-types, we mapped
the genome-wide occupancy of AcAPE1 in multiple different cell lines, including pancreatic
cancer MIA PaCa-2, breast cancer MDA-MB-231, and mouse embryonic fibroblast (MEF) cells.
Using the AcAPE1 peaks defined by Macs2, we determined that a significant (p<0.001) number
of peaks were found in the promoter regions of genes, defined as ±3 kb from the transcriptional
start site (TSS), by permutation tests (Fig 1C). We also observed a significant enrichment
(p<0.001) of AcAPE1 peaks in genebodies (Fig 1C). We repeated these results in multiple cell
lines and were able to achieve similar results for all cell lines used (Fig 1D-G). It is interesting to
note that although AcAPE1 peaks are often found in gene-body regions, we observed the
enrichment of high-confidence AcAPE1 peaks at promoters even though promoters make up only
<1% of the genome.
Using publicly available ChIP-seq data for histone markers H3K27ac, H3K4me1,
H3K4me2, and H3K9me3, and ATAC-seq, all in A549 cell line, we determined that AcAPE1
binding sites are found in active chromatin regions (Fig 1A)[100]. Indeed, AcAPE1 is positively
correlated with active marks and chromatin accessibility denoted by H3K27ac ChIP-seq and
ATAC-seq signal respectively, but is absent from heterochromatic regions marked by H3K9me3
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(Fig 1A,G). Having seen a positive correlation between AcAPE1 signal and marks of active
chromatin, we investigated the distribution of AcAPE1 ChIP-seq peaks. These results lead us to
believe that AcAPE1 preferentially binds to active chromatin.
Our genome-wide spearman correlations showed that there is a strong correlation
between enhancer marker H3K4me1 (spearman = 0.82) and AcAPE1 (Fig 1G)[101]. We also
observed a strong correlation between active enhancer marker H3K27ac and AcAPE1 (spearman
= 0.83) (Fig 1G)[101]. We further investigated these relationships and found that AcAPE1 can be
found at active enhancers located in intergenic regions (Fig 2A). To examine this phenomenon
genome-wide, we sorted the H3K27ac peaks by their strength, and found that AcAPE1
enrichment is positively correlated with H3K27ac in multiple cell lines (Fig 2B,D). Similarly,
AcAPE1 signal is positively correlated with the strength of H3K4me1 peaks indicative of its
association with enhancers (Fig 2C). Looking at previously identified enhancer regions, we found
that a significant number (p<0.001) of active distal and proximal enhancers have an overlapping
AcAPE1 peak by permutation tests (Fig 2E)[99]. To further test the relationship between active
enhancers and AcAPE1, we examined open chromatin regions identified by publicly available
ATAC-seq data in A549 cells[100]. Sorting the ATAC-seq peaks by strength, we see correlation
with AcAPE1 signal (Fig 2F). Together, these results show AcAPE1 has a strong propensity to
bind active enhancers and gene promoters.
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Figure 1: AcAPE1 correlates with promoters and active chromatin histone markers. (A)
Genome browser view of AcAPE1 ChIP-seq signal showing peak overlap with known active
chromatin markers near a gene TSS. (B,C) AcAPE1 ChIP-seq peak distribution in A549 cells.
(D-F) AcAPE1 ChIP-seq peak distribution in MEF cells (D), human pancreatic cancer cell line
MIA PaCa-2 (E), and human breast cancer cell line MDA-MB231 (F). (G) Spearman correlation
of 250bp bins for AcAPE1 ChIP-seq, various histone marker ChIP-seqs, and ATAC-seq.

33

34

34

35

Figure 2: AcAPE1 can be found at active enhancers. (A) Genome browser views in A549 cells
showing overlap between AcAPE1 ChIP-seq signal and active enhancer histone markers
H3K27ac and H3K4me1. (B) A549 AcAPE1 (Left) and H3K27ac (Right) ChIP-seq signal at
H3K27ac ChIP-seq peaks sorted by descending strength. (C) MDA-MB231 AcAPE1 (Left) and
H3K27ac (Right) ChIP-seq signal at H3K27ac ChIP-seq peaks sorted by descending strength. (D)
A549 AcAPE1 (Left) and H3K4me1 (Right) ChIP-seq signal at H3K4me1 ChIP-seq peaks sorted
by descending strength. (E) Known enhancers from A549 cells classified as active or inactive by
their H3K27ac peak status, and proximity to the nearest gene and overlap with AcAPE1 ChIP-seq
peaks. (F) A549 AcAPE1 (Left) and ATAC-seq (Right) signal at ATAC-seq peaks.
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AcAPE1 is prominent throughout the bodies of actively transcribed genes.
When looking at publicly available ChIP-seq data in A549 cells we found a strong correlation
between the binding locations of AcAPE1 and many transcription factors (TFs) (Fig3A). This is
consistent with AcAPE1 locating to active regulatory regions (Fig 1B). Therefore, we tested if
AcAPE1 occupancy correlates with gene transcription status. To determine transcription status,
we reprocessed publicly available GRO-seq data in A549 cell line[102] and compared the signal
to our AcAPE1 ChIP-seq data. By examining genome browser views of AcAPE1 and GRO-seq
signals, we found instances where AcAPE1 is enriched inside transcribed genes (Fig 3B). To
understand if a gene was actively transcribing or paused, we calculated the pausing index, which
is the ratio of GRO-seq signal at the 5’ end (TSS+500bp) versus inside the gene-body (excluding
500bp near the 5’ end)[103]. We then sorted these genes by their pausing index and confirmed
their relative transcriptional status by measuring the PolR2α ChIP-seq levels along the genes (Fig
3C)[100]. Comparing to AcAPE1 ChIP-seq signal over these genes, we see that AcAPE1 signal
can be found throughout the genebody of the more actively transcribing genes (Fig 3C). Paused
genes, where PolR2a is restricted to the TSS, only show enrichment of AcAPE1 near the TSS and
not in the gene-bodies (Fig 3C). To further confirm the above results, we split active genes into
quartiles; Least Paused, Less Paused, More Paused, and Most Paused, and determined the reads
per kilobase per million mapped reads (RPKM) normalized AcAPE1 signal in all these quartiles
(Fig 3D). We found there is significantly more AcAPE1 in the actively transcribing genes than
the paused genes by Wilcox test (p<2.2e-16). Altogether, these results indicate that AcAPE1 is
binding to active promoters as well as inside the bodies of transcribing genes.
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Figure 3: AcAPE1 can be found in the promoters and genebodies of actively transcribing
genes. (A) Spearman correlations of various transcription factor ChIP-seqs of and AcAPE1 over
250bp bins. (B) Genome browser views of AcAPE1 and publicly available GRO-seq, both in
A549 cells, show similar binding patterns across multiple genes. (C) AcAPE1 (Left) and PolR2α
(Right) ChIP-seq signal at genes sorted by their pausing index, calculated from GRO-seq data.
(D) The RPKM normalized AcAPE1 signal in the bodies of genes categorized by pausing index
quartiles. Wilcox test was used to determine significance (p<2.2e-16).
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Association of AcAPE1 with promoters and enhancers correlates with G4.
Like AcAPE1, G4 DNA are primarily enriched in the promoter and enhancer regions [78-80], and
we recently found a strong association between AcAPE1 enrichment and G4 formation in these
regions of A549 cells [85]. To examine further correlation between G4 and AcAPE1 we mapped
AcAPE1 chromatin binding by ChIP-seq in human blood cell line K562 and downloaded publicly
available G-quadruplex ChIP-seq (G4 ChIP-seq) in this cell line. We called peaks with Macs2
and determined their genome-wide distribution with ChIPseeker [95]. Similar to our findings in
other cell lines (Fig. 1D-G) we found that AcAPE1 showed significant enrichment (p<0.001) in
the promoter regions (±3kb from TSS) of genes by permutation tests (Fig 4A). We also found that
G4 is highly enriched in promoter regions as was previously demonstrated (Fig 4B) [85]. Sorting
G4 peaks by strength, we found that AcAPE1 is found at the strongest G4 peaks (Fig 4C).
Enrichment of AcAPE1 with promoters and enhancers is damage independent.
AcAPE1 enrichment at enhancer-promoter regions raised two possibilities: (1) these regions are
prone to AP site formation, or (2) they contain APE1 target sequences, presumably G4. To
investigate, we treated A549 cells with 0.5 mM hydrogen peroxide (H2O2) for 30 minutes to
induce DNA damage and mapped AcAPE1 enrichment by ChIP-seq. Upon H2O2 treatment, we
found a decrease in AcAPE1 enrichment at regions called as peaks in the untreated sample (Fig
5A). This pattern was seen throughout the genome, regardless of the proximity to genes (Fig 5A,
bottom). Surprisingly, when we look at the distribution of AcAPE1 peaks in the control sample
compared to the H2O2-treated sample we found no significant differences (Fig 5B). Both show a
high proportion of peaks in the promoters and gene bodies. However, when we examined the
AcAPE1 signal intensity at H2O2-treated samples we saw a marked decrease after H2O2 treatment
(Fig 5C,D). These results indicate that H2O2 treatment results in decreased AcAPE1 occupancy at
locations that were already preferentially targeted by AcAPE1 in the absence of DNA damage.
To help better determine the degree of difference in signal intensity between the H2O2-treated
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Figure 4: AcAPE1 and G4 can be found at similar genomic regions. (A) AcAPE1 ChIP-seq
peak distribution in K562 cells. (B) Publicly available G4 ChIP-seq peak distribution in K562
cells. (C) K562 AcAPE1 (Left) and G4 (Right) ChIP-seq signal at G4 ChIP-seq peaks sorted by
descending strength.
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Figure 5: (A) Genome browser views of AcAPE1 ChIP-seq signal in control vs H2O2-treated
A549 cells. (B) Control A549 cell AcAPE1 ChIP-seq peak distributions (top) and H2O2-treated
A549 cell AcAPE1 ChIP-seq peak distributions (bottom). (C) (Left) H2O2-treated AcAPE1 ChIPseq signal at H2O2-treated AcAPE1 peaks. (Right) Control A549 AcAPE1 ChIP-seq signal at
H2O2-treated AcAPE1 ChIP-seq peaks sorted by descending strength. (D) (Left) Control A549
AcAPE1 ChIP-seq signal at Control AcAPE1 peaks sorted by descending strength. (Right) H2O2treated A549 AcAPE1 ChIP-seq signal at Control A549 AcAPE1 ChIP-seq peaks sorted by
descending strength. (E) Profiles of Control AcAPE1 and H2O2-treated AcAPE1 ChIP-seq
signals, normalized to inputs, at genebodies ±3Kb.
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samples and control across the gene-body, we normalized the H2O2-treated and control AcAPE1
signals with Input signal and determined the binding profiles (Fig 5E). Again, the promoters show
higher enrichment for control AcAPE1 than H2O2-treated AcAPE1. There is also a lower
background level for control AcAPE1 than the H2O2-treated AcAPE1 sample. These results
indicate that H2O2 treatment results in decreased AcAPE1 occupancy at locations preferentially
targeted by AcAPE1 in the absence of DNA damage or DNA damage induced relocalization of
AcAPE1 to other regions in the genome randomly. We surmised that H2O2 may have multiple
effects on other factors than DNA damage alone. Therefore, AcAPE1 recruitment to promoters
and enhancers is AP site independent.
Knockdown of APE1 leads to differences in gene expression
To examine whether knockdown of APE1 has any impact on the expression of the observed
AcAPE1 enriched genes we performed bulk RNA-seq of A549 cells with APE1 knockdown by
shRNA. This resulted in 3,485 differentially expressed (DE) genes. We found that 66.1% of these
DE genes had an AcAPE1 ChIP-seq peak in the genebody OR promoter (TSS-3Kb) (Fig 6A). We
also determined that 44.0% of the DE genes had an AcAPE1 ChIP-seq peak in both the genebody
AND promoter (Fig 6A). By doing a pathway analysis of the differentially expressed genes in
FunSet, we found one of the top hits was DNA damage response pathway [104]. This pathway
was of interest to us because of the known APE1 role in DNA damage response. We found that
some of the genes in this pathway are overexpressed upon knockdown of APE1, and others are
suppressed, which could be a response to counteract DNA damage response in the absence of
APE1 (Fig 6B). More mechanistic studies are necessary to understand the biological significance
of association of AcAPE1 to promoter/enhancers, as well as how AcAPE1 impacts gene
expression both positively and negatively to maintain cellular functions.
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Figure 6: Knockdown of AcAPE1 leads to DEGs that correlate with AcAPE1 ChIP-seq
peaks. (A) Euler diagram of the DEGs with an AcAPE1 ChIP-seq peak in the promoter
(Promoter), genebody (Genebody), both (center), or neither (Non-overlapping DEGs). (B) DNA
damage response pathway genes identified by FunSet and their log2(FC).
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Chapter 4
Discussion
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One of the most commonly found endogenous damage in the genome is AP sites, which are
generated either spontaneously, or after removal of the damaged bases by the glycosylation in
BER pathway. These AP sites, if left unrepaired, can inhibit transcription by blocking the
elongating RNA polymerase complex, or induce mutations due to the misincorporation of bases
opposite the AP site by DNA polymerases. Recent genome-wide mapping revealed that
distributions of AP sites in the genome are non-random, mostly occurring in the euchromatin
regions. APE1 is the primary enzyme involved in repairing AP sites throughout the genome via
the highly conserved (BER) pathway [5-7]. Therefore, APE1 should have a role in suppressing
mutagenesis and unblocking transcription at AP sites. Indeed, research indicates APE1 plays a
very large role in the cell. Studies have shown that APE1 is an essential protein in embryogenesis,
with APE1-null mice being embryonic lethal resulting in no APE1-null mouse embryonic
fibroblast (MEF) cell lines being created [24]. Studies in our laboratory, and others, suggest
APE1 is a multifunctional protein and specific regions of the N- and C-termini of APE1 are
responsible for its diverse biological roles. The C-terminal globular domain catalyzes AP site
cleavage for BER. The N-terminal (1-42 amino acids) is unstructured, but it contains positively
charged Lysine residues, and plays regulatory roles for both DNA repair and transcriptional
regulatory functions. Two Lys residues (Lys6 and Lys 7) in the N-terminal domain of chromatinbound APE1 are acetylated (AcAPE1) by histone acetyltransferase p300. Acetylation modulates
both its DNA repair transcriptional regulatory functions in vitro and in cells. By using APE1 null
MEF cells, our lab previously showed that DNA repair domain and lysine’s 6 and 7 are crucial to
cell survival and proliferation [29]. AcAPE1 was found to have elevated levels in a variety of
cancers, and its association with drug resistance and patient’s survival highlighting its importance
in cancer [65, 74]. Our lab has previously shown that acetylation of APE1 increases endonuclease
function of APE1 and regulates gene expression by modulating transcription factor loading on the
chromatin [75]. Despite involvement of AcAPE1 in multiple biological processes, little is known
about genome-wide occupancy/distribution of AcAPE1. Our recently published study shows
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APE1 is enriched primarily in the promoters/enhancers and gene bodies in A549 cell line, and the
APE1 occupancy most frequently contained guanine rich regions that can form G-quadruplex
(G4) structures [85]. This study set out to determine whether the region-specific enrichment of
AcAPE1 was cell-type specific, or a general cellular phenomenon and the biological significance
of site-specific AcAPE1 enrichment. In this study, we show that AcAPE1 is preferentially bound
to transcriptionally active regions in the genome. Further, we demonstrate that induction of
damage, although decreased the number of peaks, does not change the distribution. We show that
knockdown of APE1 alters expression of most AcAPE1 enriched genes. Alteration of expression
of hundreds of genes upon knockdown of APE1 lead us to believe the role of AcAPE1 in the cell
can be wide-reaching. This raised two possibilities by which site-specific binding/enrichment of
AcAPE1 may facilitate expression of these genes: either by promoting formation of G4 and
loading TFs to promoter/enhancer regions, or through preferentially repairing AP site damage in
these regions.
By generating AcAPE1 ChIP-seq results in multiple cell lines we determined that, while
the number of the peaks is variable, the overall distribution stays similar between different
mammalian cell types. Close to a quarter of the peaks in all cell lines were found in the promoter
regions, with over a third of the peaks found in gene bodies. The variability of these numbers may
be due to batch effects, or there may be real differences in the cell types. To further investigate
the regions AcAPE1 was binding to, we correlated our AcAPE1 ChIP-seq peaks with publicly
available histone ChIP-seq datasets and ATAC-seq data. We could see a strong correlation
between AcAPE1 and enhancer markers H3K4me1 and H3K27ac, as well as with ATAC-seq.
These markers show that AcAPE1 is targeting active chromatin regions, specifically active
enhancers, regardless of their proximity to genes.
After determining that AcAPE1 preferentially binds to promoters and enhancers, we
looked at the transcription status of these genes. Using publicly available GRO-seq data and
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sorting genes by their pausing index, we found that AcAPE1 can be found in the actively
transcribing genes more frequently than the paused, or inactive, genes. Paused genes showed
AcAPE1 signal strongest near the TSS, while actively transcribing genes had significantly more
AcAPE1 throughout their gene bodies. Together, these results indicate that AcAPE1 binds not
only active promoters, but also the gene bodies of actively transcribing genes.
AcAPE1 enrichment at enhancer-promoter regions raised possibilities that these regions
are prone to AP site formation, or they contain target sequences that APE1 preferentially bind or
both. The observations that H2O2 treatment, which induces AP sites, did not change the AcAPE1
genomic distribution highlight that AcAPE1 enrichment is independent of damage or
alternatively these damaging agents may preferentially induce damage in these regions.
Interestingly, our recent published and current study demonstrate that AcAPE1 peaks strongly
correlated with promoter/enhancers containing G4 in A549 cells, and in K562 cells although
weakly [85]. AcAPE1 peaks overlapped with enhancer markers and TFs at the promoters [85].
Recently, another study from our lab confirmed that G4 and APE1 co-localize by high resolution
(110 nm) structured Illumination Microscopy (SIM) and proximity ligation assay [105]. APE1
knockdown (KD) in MiaPaca2 and PANC1 cells reduced G4 staining and enrichment of G4 in
KRAS promoter [105]. This study showed that knockdown of APE1 reduced the formation of G4
in the genome as well as in KRAS promoter and affects its expression. In vitro, recombinant
APE1 binds G4 with high affinity (like AP site binding) and in KRAS and MYC promoter G4 in
cells, and downregulation of APE1 affect G4 formation KRAS expression. Therefore, AcAPE1
associates with promoter/enhancer through binding to G4. Human genome contains 300,000 to
700,000 potential G4 forming sequences (PQS), mostly in the promoter, 5’UTR, in exons in the
transcribed gene and telomere regions [78]. Many cancer driver oncogenes, including KRAS, cMYC and VEGF, have G4 in their promoters [106]. Genes marked by endogenous promoter G4s
in chromatin show higher transcriptional output than their non-G4 counterparts. Increasing
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evidence suggests that G4s can act as positive regulators of transcription by multiple mechanisms.
This includes the role of G4s in facilitating TF and RNA Pol II loading. G4s can influence the
formation and long-range enhancer-promoter loops and activate gene expression. We propose a
mechanism by which APE1 regulates gene expression through a mechanism that involves
facilitating the formation of promoter/enhancer G4 structure and loading of the TFs to the
promoter region. We believe APE1 associates with promoter enhancer through targeting G4 and
facilities TFs bindings. This idea is based on the following results: (a) AcAPE1 is exclusively a
chromatin-bound protein, it is site-specifically (promoter/enhancer) enriched and show genomewide, strong correlations with p300 and G4; (b) inhibition APE1 or its acetylation of Ly6 and
Lys7 affects expression of hundreds of genes; (c) APE1 colocalizes and interacts with G4
structures in cells, and recombinant APE1 can directly bind KRAS promoter G4 structure in vitro;
(d) Downregulation of APE1 reduces stable G4 formation, loading of MAZ and PARP1 on
KRAS promoter, and KRAS expression.
Since APE1 knockdown enriches AP sites in promoters, and gene bodies, and SIRT1
deacetylates APE1 Lys6 and Lys7 in cell [73], and SIRT1 downregulation increased AP sites in
the genome, we cannot eliminate the alternative possibility that APE1 binds and resides at G4 to
preferentially repairs endogenous damage in the transcribed genes regions. We know that active
promoters/enhancers are open chromatin, which make them susceptible to endogenous damage
[107, 108]. During transcription, histones and 5-methyl Cytosines at CpG sites in
promoter/enhancers are demethylated by an oxidative process that generates ROS [109, 110],
which damage DNA by oxidizing bases [111-113] such as 8-oxo-Guanine. AP sites or SSBs
generated after their removal by specific glycosylases disrupt the loading of transcription factors
and block elongation by RNA Polymerase II, faster and preferential repair of these damages is
essential to maintain gene expression. More experiments are necessary to examine the hypothesis
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that APE1 and AcAPE1 bind and reside at G4 in the promoter/enhancer regions, making
preferential damage repair.
Previous studies have shown that G4 DNA are primarily enriched in regulatory regions of
chromatin, including promoters and enhancers [78-80]. We previously found a strong association
between AcAPE1 enrichment and G4 formations in these regions [85]. Here, we determined that
AcAPE1 and G4 do correlate together in gene promoter regions based on ChIP-seq peak strength
in K562 cell line.
While it is known that APE1 plays many roles within the cell, it was not clear what role
AcAPE1 played when bound to enhancer-promoter regions. Previously, our lab has shown that
induction of DNA damage, through MMS treatment, enhance APE1 acetylation and its
occupancy on chromatin [85]. In this study, we determined that AcAPE1 occupancy of enhancerpromoter regions is damage independent by using hydrogen peroxide treatment. We did see a
change in peak intensities after treatment with H2O2, but we did not see an overall shift in
AcAPE1 peak distributions post treatment. These results indicate that H2O2 treatment leads to
decreased AcAPE1 occupancy in locations already preferentially targeted by AcAPE1 in the
absence of DNA damage, and relocation of AcAPE1 to other regions in the genome randomly.
There is a possibility that H2O2 treatment is having multiple effects on factors other than DNA
damage, so further investigation into the differences seen between untreated and treated AcAPE1
distributions will be important. At this point, we can say recruitment of AcAPE1 to enhancerpromoter regions is AP site independent.
It is known that AcAPE1 is important in regulating gene expression through redox
activity with other transcription factors [34]. To test the expression of observed AcAPE1 enriched
genes upon APE1 knockdown, we performed bulk RNA-seq of APE1 knockdown by shRNA. We
determined that a majority of the differentially expressed genes had an AcAPE1 peak in their
promoter or enhancer, with most of these genes having AcAPE1 in both an enhancer and
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promoter. One of the top gene ontology hits was for DNA damage response pathway, which is of
interest because of the known role APE1 plays in DNA damage response.
Here, we propose that AcAPE1 preferentially targets active chromatin regions, including
active enhancers and promoters. The binding of AcAPE1 to these regions appears to be consistent
throughout a variety of mammalian cell types, leading us to believe that AcAPE1 performs a
similar role in all cell types. The overall abundance of APE1 shows that it is an important
molecule in maintaining cell growth and proliferation.
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